Breast Cancer News

Kisqali® Improves Outcomes for Premenopausal Women with HR+/HER2- Advanced Breast Cancer (November 14, 2017)

Premenopausal breast cancer is a biologically distinct and more aggressive disease than postmenopausal breast cancer and is the leading cause of cancer death in women 20-59 years old.1,2 ,3 Historically there younger women were treated the same as their older counterparts, researchers however have more recently begun to focus on improving the treatment outcomes for […]

Nerlynx Modestly Improves Survival of HER 2-Positive Early Stage Breast Cancer (November 1, 2017)

Positive results from the clinical trial evaluating neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer following trastuzumab-based therapy (ExteNET trial) were presented at the European Society of Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. About HER2-Positive Breast Cancer Approximately 20% to 25% of breast cancers over-express the HER2 protein. HER2-positive […]

Verzenio Demonstrates Superior Progression-Free Survival in Advanced Breast Cancer (October 30, 2017)

Recently released clinical trial results from the Phase 3 MONARCH 2 study showed that Verzenio (abemaciclib), a cyclin-dependent kinase (CDK) 4 & 6 inhibitor, when administered in combination with fulvestrant, significantly improves the time to cancer progression compared to treatment with fulvestrant alone in women with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), […]

Radius Health Receives FDA Fast Track Designation for Elacestrant (October 26, 2017)

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for elacestrant, an investigational oral selective estrogen receptor down-regulator/degrader (SERD) as a treatment of women with ER+ and HER2- advanced or metastatic breast cancer. Fast Track designation is a process designed to facilitate the development and expedite the review of new therapies to […]

Immunotherapy Active Against Triple-Negative Breast Cancer (October 12, 2017)

October is breast cancer awareness month and patients with triple-negative breast cancer (TNBC) should be aware that data from two clinical trials provide additional evidence that they may derive benefit from checkpoint inhibitor therapy.1-4 About Triple Negative Breast Cancer Approximately 12% of breast cancers are triple-negative breast cancers, meaning that they are estrogen-receptor negative (ER-), […]

LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations (October 10, 2017)

LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes also appears to slowe the progression of breast cancer caused in part by mutations in the BRCA gene.  BRCA is an inherited condition that causes up to 3% of all breast cancers. BRCA + breast cancer is particularly […]

FDA approves new treatment for certain advanced or metastatic breast cancers (October 5, 2017)

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy). Verzenio is approved to be given in combination with an endocrine […]

Annual Mammography Starting at Age 40 Prevents the Most Cancer Deaths (September 13, 2017)

When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue to spark emotional debates. A new study compares the number of deaths that might be prevented as a result of three of the most widely discussed recommendations for screening mammography. Published early online in Cancer, […]

FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2-Positive Metastatic Breast Cancer (August 30, 2017)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer who have been treated with Herceptin and Perjeta and have disease progression after ado-trastuzumab (T-DM1). Breakthrough Therapy designation is designed to […]

Nipple-Sparing Mastectomy Has Low Rate of Breast Cancer Recurrence (August 1, 2017)

Investigators say most women with breast cancer are eligible for this type of mastectomy, which leaves the natural nipple in place Women with breast cancer who undergo nipple-sparing mastectomy (NSM) have a low rate of the cancer returning within the first five years, when most recurrences in the breast are diagnosed, findings of a single-center […]

Latest Breast Cancer News By Stage


Carcinoma In Situ Breast cancer

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal of Clinical Oncology. There is an estimated 3.1 million breast cancer survivors alive today in the United States. At present, […]

Quality of Life Helps Determine Type of Hormone Treatment in Early Breast Cancer (January 20, 2016)

Quality of life issues and different side effects caused by treatment may help determine which type of hormone therapy is most appropriate for postmenopausal women with ductal carcinoma in situ, particularly among women 60 years of age or older. These results were recently published in The Lancet. Hormone-positive breast cancers, which comprise approximately 75% of […]

Radiation Essential to Controlling Long-Term Recurrence in Women With Early Form of Breast Cancer (October 1, 2015)

Doctors have reported that rates of breast cancer recurrences continue to increase, even after 12 years, among patients with ductal carcinoma in situ (DCIS) who do not receive radiation therapy as part of their treatment regimen. These results were recently published in the Journal of Clinical Oncology. DCIS is considered to be the earliest type […]

Biomarker May Help Improve Treatment of Triple-Negative Breast Cancer (September 8, 2015)

Researchers have found a biomarker that appears active in the growth and spread of triple-negative breast cancer. Known as interleukin-13 receptor alpha 2 (IL13Ralpha2), the biomarker may help doctors identify patients at high risk of disease spread and potentially provide a target for treatment. These findings were reported in Breast Cancer Research. The majority of […]

Women with Early Breast Cancer Have Fewer Side Effects with Shorter Courses of Radiation (September 1, 2015)

Women with early breast cancer have fewer side effects when they’re treated with shorter courses of radiation at higher doses than with conventional radiation to the whole breast. These findings were reported in JAMA Oncology.[1] Treatment with shorter course of radiation at higher doses is known as hypofractionated radiation therapy. This approach allows for less […]

More Carcinoma In Situ Breast cancer

Inflammatory Breast Cancer

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal of Clinical Oncology. There is an estimated 3.1 million breast cancer survivors alive today in the United States. At present, […]

Breast Cancer Research: Have We Made Progress? (January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we Made Progress? Recent Study Finds That African American Women Less Likely To Receive Standard Breast Cancer Treatment Breast Cancer […]

Walk or Run Your Way to a Reduced Risk of Breast Cancer (September 24, 2014)

Want to reduce your risk of breast cancer? Lace up those shoes and get moving—because exercise has a significant impact. There is a growing body of evidence to indicate that exercise is crucial to reducing the risk of cancer. Now a new study has put a number on that reduced risk: 41.5 percent.1 That’s right: […]

Risk of Breast Cancer Recurrence Doesn’t Increase with TNF Inhibitor Use (August 28, 2014)

According to the results of a recently published study from Swedish investigators treatment with tumor necrosis factor inhibitors (TNF) does not appear to increase the rate of breast cancer recurrence among patients with rheumatoid arthritis (RA).  The study’s results should help to allay any concerns about the potential for tumor necrosis factor (TNF) inhibitors to […]

Ask the Expert: Making Informed Decisions about Breast Reconstruction (June 18, 2014)

July 16, 2014 at 6:30pm EST CancerConnect live Web Chat with an Expert series presents:  “Making Informed Decisions about Breast Reconstruction.”  On July 16, 2014 at 6:30pm EST you will have the opportunity to engage with a breast cancer expert who will discuss and answer participants’ questions about reconstruction after breast cancer surgery during a […]

More Inflammatory Breast Cancer

Metastatic Breast Cancer

FDA approves new treatment for certain advanced or metastatic breast cancers (October 5, 2017)

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy). Verzenio is approved to be given in combination with an endocrine […]

FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2-Positive Metastatic Breast Cancer (August 30, 2017)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer who have been treated with Herceptin and Perjeta and have disease progression after ado-trastuzumab (T-DM1). Breakthrough Therapy designation is designed to […]

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer (March 16, 2017)

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination benefits all such women and leads to improved survival without cancer recurrence. The interim results from a large clinical […]

Keytruda®/Halaven® Combo May Be Effective in Advanced Triple-Negative Breast Cancer (January 9, 2017)

The investigative treatment combination including Keytruda® (pembrolizumab) plus Halaven® (eribulin) could provide a potential therapeutic option for patients with advanced triple-negative breast cancer (TNBC) whose disease has advanced following prior therapies. These results were recently presented at the 2016 annual San Antonio Breast Cancer Symposium (SABCS). Approximately 12% of breast cancers are triple-negative breast cancers, […]

Ribociclib Offers ‘Paradigm Shift’ in Advanced Breast Cancer (October 26, 2016)

The investigational drug ribociclib (formerly LEE011) when combined with Femera (letrozole) for the initial treatment of postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer leads to improved survival without cancer recurrence. The interim results from a large clinical trial presented at the 2016 European Society for Medical Oncology (ESMO) meeting and published in the […]

More Metastatic Breast Cancer

Recurrent Breast Cancer

Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer (June 30, 2016)

The combination of the immune stimulating agent Tecentriq™ (atezolizumab), plus the chemotherapy agent Abraxane® (nab-paclitaxel) is effective in providing anti-cancer responses among patients with advanced triple-negative breast cancer (TNBC). These results were recently reported at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Approximately 10-20% of breast cancers are referred to […]

Directly Involving Patients Drives Participation in Metastatic Breast Cancer Study (June 22, 2016)

A clinical study to accelerate research in metastatic breast cancer has rapidly enrolled participants through direct collaboration with patients. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). One large challenge in furthering research in the field of cancer is obtaining enough samples of tumor tissue […]

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal of Clinical Oncology. There is an estimated 3.1 million breast cancer survivors alive today in the United States. At present, […]

Blood Test May Predict Cancer Recurrences Earlier than Standard Methods (October 26, 2015)

A blood test that can detect circulating DNA from cancer cells appears to accurately predict the risk of a breast cancer recurrence 8 months earlier than standard detection methods among women with high-risk breast cancer. However, further study is necessary to confirm these findings and understand their benefit in a clinical setting. These results were […]

Abemaciclib Receives FDA Breakthrough Therapy Designation in Advanced Breast Cancer (October 9, 2015)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. According to the FDA, Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended […]

More Recurrent Breast Cancer

Screening/Prevention Breast Cancer

It’s in the Genes: Top 5 Things to Know about Genetic Testing (July 8, 2016)

Advances in genetic testing are offering women more information than ever before about their genetic makeup and are providing opportunities for empowered decision-making related to a wide range of health issues. In this recurring column, experts provide vital information about how genetic testing suits one’s individual needs, potential risks and benefits, and the role of […]

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its expansion into the oncology market, with a focus on advancing cancer risk screening and helping cancer prevention efforts. Counsyl’s […]

3D Mammography Proves More Accurate in Breast Cancer Detection (March 31, 2016)

Longer follow-up evaluating digital breast tomosynthesis (DBT), also referred to as 3D mammography, demonstrates its continued effectiveness compared to standard digital mammography (DM) when screening for breast cancer. These results were recently published in JAMA Oncology. It is well established that survival rates for treatment of early breast cancer are significantly superior to survival rates […]

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal of Clinical Oncology. There is an estimated 3.1 million breast cancer survivors alive today in the United States. At present, […]

Blood Test May Predict Cancer Recurrences Earlier than Standard Methods (October 26, 2015)

A blood test that can detect circulating DNA from cancer cells appears to accurately predict the risk of a breast cancer recurrence 8 months earlier than standard detection methods among women with high-risk breast cancer. However, further study is necessary to confirm these findings and understand their benefit in a clinical setting. These results were […]

More Screening/Prevention Breast Cancer

Stage I Node Negative Breast Cancer

MammaPrint Might Help Identify Breast Cancer Patients Who Could Safely Opt Out of Chemo (September 7, 2016)

MammaPrint, a 70-gene signature test, might help healthcare providers and patients determine whether they will derive a benefit from chemotherapy, or if they could safely choose to not receive chemotherapy for early-stage breast cancer. These results need to be validated, and compared to other tests in order to confirm findings and determine true clinical utility […]

Neratinib Improves Cancer-Free Survival in Early Breast Cancer (July 27, 2016)

The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast cancer. Approximately 20-30% of breast cancer is referred to as human epidermal growth factor receptor-2 (HER2)-positive.  This means that the breast cancer cells have too many HER2 proteins on […]

Treatment with Aromatase Inhibitors for 10 Years Improves Cancer-Free Survival in Breast Cancer (June 7, 2016)

Among postmenopausal women with hormone-positive, early breast cancer, treatment with aromatase inhibitors (AIs) for 10 years significantly improves cancer-free survival, compared to the 5-year standard length of AI treatment.  However, quality of life issues, bone density concerns, and a patient’s risk of a recurrence should be taken into consideration to determine the optimal length of […]

Some Premenopausal Women Benefit from Exemestane Compared to Tamoxifen (April 28, 2016)

Among premenopausal women with hormone-positive, early breast cancer who are considered to have a high risk of a cancer recurrence, the use of Aromasin® (exemestane) versus tamoxifen improves cancer-free survival at 5 years. These results were recently published in the Journal of Clinical Oncology. The majority of breast cancers, referred to as hormone-positive breast cancers, […]

Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival (March 28, 2016)

Premenopausal women who have been diagnosed with breast cancer have improved survival if their chemotherapy doses are delivered every two weeks, compared to every three weeks. These results were recently presented at the 2016 European Breast Cancer Conference (EBCC-10) in the Netherlands. Chemotherapy following surgery is a standard treatment option for premenopausal women diagnosed with […]

More Stage I Node Negative Breast Cancer

Stages II-III Breast Cancer

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer (March 16, 2017)

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination benefits all such women and leads to improved survival without cancer recurrence. The interim results from a large clinical […]

Neratinib Improves Cancer-Free Survival in Early Breast Cancer (July 27, 2016)

The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast cancer. Approximately 20-30% of breast cancer is referred to as human epidermal growth factor receptor-2 (HER2)-positive.  This means that the breast cancer cells have too many HER2 proteins on […]

Some Premenopausal Women Benefit from Exemestane Compared to Tamoxifen (April 28, 2016)

Among premenopausal women with hormone-positive, early breast cancer who are considered to have a high risk of a cancer recurrence, the use of Aromasin® (exemestane) versus tamoxifen improves cancer-free survival at 5 years. These results were recently published in the Journal of Clinical Oncology. The majority of breast cancers, referred to as hormone-positive breast cancers, […]

Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival (March 28, 2016)

Premenopausal women who have been diagnosed with breast cancer have improved survival if their chemotherapy doses are delivered every two weeks, compared to every three weeks. These results were recently presented at the 2016 European Breast Cancer Conference (EBCC-10) in the Netherlands. Chemotherapy following surgery is a standard treatment option for premenopausal women diagnosed with […]

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal of Clinical Oncology. There is an estimated 3.1 million breast cancer survivors alive today in the United States. At present, […]

More Stages II-III Breast Cancer

Supportive Care Breast Cancer

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal of Clinical Oncology. There is an estimated 3.1 million breast cancer survivors alive today in the United States. At present, […]

Breast Cancer Research: Have We Made Progress? (January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we Made Progress? Recent Study Finds That African American Women Less Likely To Receive Standard Breast Cancer Treatment Breast Cancer […]

Risk of Breast Cancer Recurrence Doesn’t Increase with TNF Inhibitor Use (August 28, 2014)

According to the results of a recently published study from Swedish investigators treatment with tumor necrosis factor inhibitors (TNF) does not appear to increase the rate of breast cancer recurrence among patients with rheumatoid arthritis (RA).  The study’s results should help to allay any concerns about the potential for tumor necrosis factor (TNF) inhibitors to […]

Ask the Expert: Making Informed Decisions about Breast Reconstruction (June 18, 2014)

July 16, 2014 at 6:30pm EST CancerConnect live Web Chat with an Expert series presents:  “Making Informed Decisions about Breast Reconstruction.”  On July 16, 2014 at 6:30pm EST you will have the opportunity to engage with a breast cancer expert who will discuss and answer participants’ questions about reconstruction after breast cancer surgery during a […]

Ask the Expert: Breast Cancer, Diet and Exercise (May 19, 2014)

CancerConnect recently partnered with Dana-Farber to provide you with the opportunity to engage with a breast cancer expert, Jennifer A. Ligibel, MD, of the Susan F. Smith Center for Women’s Cancers at Dana-Farber. On May 7 and 8, 2014, Dr. Ligibel guest-moderated on CancerConnect for a question-and-answer session on “Breast Cancer, Diet and Exercise.” CancerConnect […]

More Supportive Care Breast Cancer